Poser criteria

Definitions

Poser et al. define several concepts. The most important for diagnosis are:

• Attack: Occurrence of a symptom of neurological dysfunction for more than 24 hours
• Clinical evidence: Neurological dysfunction demonstrable by neurological examination
• Paraclinical evidence: Demonstration by any test of the existence of a non-clinical lesion in the CNS

Diagnosis conclusions

The criteria can yield five conclusions: |CDMS – Clinically definite MS. Needs two attacks and some clinical or paraclinical evidences |LSDMS – Laboratory supported definite MS, showing oligoclonal bands and clinical or paraclinical evidences |CPMS – Clinically probable MS, with less restrict combinations. |LSPMS – Laboratory supported probable MS. Only two attacks is enough to enter this category |No MS – There is no clinical evidence of having MS.

Summary of requirements

Any of the five conclusions have subpossibilities. Here a table is shown with each one of them:

If none of these requirements is accomplished, the diagnosis is "No MS", meaning that there is not enough clinical evidence to support a clinical diagnosis of MS.

Sensitivity and specificity

Poser diagnosis of CDMS was initially reported to have a sensitivity of 87% respect postmortem autopsy examination. Poser criteria were published in 1983 and their sensitivity increased with time. For example, in 1988 a 94% specificity vs. postmortem analysis was reported Anyway, in initial cases, the sensitivity was low respect pathologically defined MS because around 25% of MS cases are silent MS cases.

Two pathologically disseminated inflammatory demyelinating lesions should be considered MS even if they are silent. Therefore, Poser criteria should be considered as deprecated.

Extension of the concepts

As more knowledge about the underlying pathology of MS has been gathered, the concepts of subclinical, preclinical and CIS have been used together with the Poser original classification.

The first manifestation of MS is the so-called clinically isolated syndrome, or CIS, which is the first isolated attack. The Poser diagnosis criteria for MS does not allow doctors normally to give an MS diagnosis until a second attack takes place. Therefore, the concept of "clinical MS", for a MS that can be diagnosed is sometimes too strong because until MS diagnosis has been established, nobody can tell whether the disease dealing with is MS.

Cases of MS before the CIS are sometimes found during other neurological inspections and are referred to as "subclinical MS". "Preclinical MS" refers to cases after the CIS but before the confirming second attack. After the second confirming attack the situation is referred to as CDMS (clinically defined multiple sclerosis).

References

References

1. Christopher J. Lisanti, Patrick Asbach, and William G. Bradley, Jr. The Ependymal "Dot-Dash" Sign: An MR Imaging Finding of Early Multiple Sclerosis, AJNR Am J Neuroradiol 26:2033–2036, September 2005
2. (March 1983). "New diagnostic criteria for multiple sclerosis: Guidelines for research protocols". Annals of Neurology.
3. Izquierdo G, Hauw J-J, Lyon-Caen O. (1985). "Value of multiple sclerosis diagnostic criteria: 70 Autopsy-confirmed cases". Arch Neurol.
4. Engell T. (July 1988). "A clinico-pathoanatomical study of multiple sclerosis diagnosis". Acta Neurol. Scand..
5. Engell T. (May 1989). "A clinical patho-anatomical study of clinically silent multiple sclerosis". Acta Neurol Scand.
6. (2008). "Subclinical MS: follow-up of four cases". European Journal of Neurology.
7. (2008). "Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile". J Neurol Neurosurg Psychiatry.
8. (Dec 2008). "The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis". J. Neuroimmunol..